论文部分内容阅读
目的:对重组人脑利钠肽治疗老年心肾综合征的疗效进行观察和探讨。方法 :选取2013年1月-2015年6月我院心内科收治的50例心肾综合征的老年患者。随机分为常规治疗组26例,常规治疗+重组人脑利钠肽组24例。对两组患者用药前后血压、心率、肌酐、尿量、EF值、心功能分级、血氧饱和度及BNP数值等变化进行观察和分析。结果:两组相比,重组人脑利钠肽治疗组较常规治疗组的心率、血压、肌酐、BNP数值下降明显,尿量、血氧饱和度上升也较快,心功能明显改善(P<0.05)。各检测指标与时间之间无明显交互作用(P>0.05)。结论:重组人脑利钠肽对心肾综合征疗效确切,不良反应较少,是临床治疗老年心肾综合征较为理想的药物。
Objective: To observe the effects of recombinant human brain natriuretic peptide in the treatment of elderly patients with cardio-renal syndrome. Methods: From January 2013 to June 2015, 50 elderly patients with cardio-renal syndrome admitted to our hospital from Department of Cardiology were selected. Randomly divided into routine treatment group 26 cases, routine treatment + recombinant human brain natriuretic peptide group 24 cases. Blood pressure, heart rate, creatinine, urine output, EF value, heart function classification, blood oxygen saturation and BNP value before and after treatment were observed and analyzed in two groups of patients. Results: Compared with the control group, heart rate, blood pressure, creatinine and BNP decreased significantly in the two groups. The urine volume and oxygen saturation increased rapidly and the cardiac function improved significantly (P < 0.05). There was no significant interaction between each test index and time (P> 0.05). Conclusion: The recombinant human brain natriuretic peptide is effective in the treatment of cardio-renal syndrome and has few adverse reactions. It is an ideal drug for the clinical treatment of elderly patients with cardio-renal syndrome.